Urologix Announces Pricing of Follow-On Offering of 5.2M Shares of Common Stock at $0.75

Urologix®, Inc.

, the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the pricing of its registered follow-on firm commitment underwritten public offering of 5,200,000 shares of its common stock at a public offering price of $0.75 per share. The public offering is expected to close on or about July 5, 2012, subject to customary closing conditions. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 780,000 shares of its common stock to cover overallotments.